Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.62 |
| ▸ | EPHX2 | P34913 | 6/20 | 0.57 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.52 |
| ▸ | CYP2J2 | P51589 | 2/20 | 0.52 |
| ▸ | POLB | P06746 | 2/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.50 |
| ▸ | HRH1 | P35367 | 1/20 | 0.48 |
| ▸ | CCR3 | P51677 | 1/20 | 0.48 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5179854 | 0.88 | EPHX2 (0.50) | KMT2AEPHX2SMN1; SMN2ALOX15HTT | |
| SCHEMBL4240704 | 0.88 | EPHX2 (0.55) | KMT2AEPHX2CYP2C9CYP2J2 | |
| SCHEMBL4244661 | 0.85 | KMT2A (0.59) | KMT2AEPHX2CYP2C9CYP2J2POLB | |
| SCHEMBL4244550 | 0.85 | EPHX2 (0.54) | KMT2AEPHX2CYP2C9CYP2J2SMN1; SMN2 | |
| SCHEMBL1811365 | 0.84 | MGLL (0.65) | KMT2AHTTMEN1 | |
| SCHEMBL5408909 | 0.81 | HRH1 (0.70) | HRH1CCR3 | |
| SCHEMBL1809368 | 0.80 | EPHX2 (0.63) | KMT2AEPHX2HTTLMNAMEN1 | |
| SCHEMBL4244649 | 0.79 | PARP10 (0.53) | EPHX2CYP2C9CYP2J2 | |
| SCHEMBL4247871 | 0.79 | KMT2A (0.62) | KMT2APOLBSMN1; SMN2MEN1NPC1 | |
| SCHEMBL1806630 | 0.78 | HRH3 (0.64) | KMT2AHTTMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090170901-A1 | Benzoyl Urea Derivatives | RICHTER GEDEON VEGYESZETI GYAR RT. (HU) | 2009-07-02 | — | — | US | disclosed |
| EP-1771429-A1 | NEW BENZOYL UREA DERIVATIVES | RICHTER GEDEON VEGYESZETI GYAR RT. (HU) | 2007-04-11 | — | — | EP | disclosed |
| WO-2006010966-A1 | NEW BENZOYL UREA DERIVATIVES | Richter Gedeon Vegyészeti Gyár Rt. (HU) | 2006-02-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090170901-A1 | Benzoyl Urea Derivatives | OPRM1, GRIN2C, GRIN3A | KMT2A 3249/4885EPHX2 1860/4885CYP2C9 639/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.